X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4784) 4784
Book Review (1273) 1273
Newsletter (981) 981
Publication (507) 507
Newspaper Article (64) 64
Conference Proceeding (47) 47
Book Chapter (35) 35
Transcript (22) 22
Magazine Article (16) 16
Trade Publication Article (5) 5
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ipilimumab (5426) 5426
immunotherapy (3029) 3029
index medicus (2945) 2945
humans (2648) 2648
melanoma (2597) 2597
oncology (2487) 2487
cancer (2008) 2008
nivolumab (1457) 1457
care and treatment (1293) 1293
male (1118) 1118
melanoma - drug therapy (1106) 1106
metastatic melanoma (1100) 1100
metastasis (1081) 1081
antibodies, monoclonal - therapeutic use (1026) 1026
research (1023) 1023
female (998) 998
pembrolizumab (907) 907
middle aged (903) 903
immunology (780) 780
survival (761) 761
aged (744) 744
chemotherapy (729) 729
drug therapy (695) 695
antibodies, monoclonal - adverse effects (636) 636
open-label (632) 632
antineoplastic agents - therapeutic use (605) 605
melanoma - pathology (593) 593
adult (569) 569
treatment outcome (562) 562
therapy (553) 553
patients (551) 551
skin neoplasms - drug therapy (549) 549
tumors (540) 540
immunotherapy - methods (522) 522
safety (512) 512
clinical trials (465) 465
pd-1 (456) 456
medical research (454) 454
analysis (437) 437
ctla-4 (432) 432
blockade (419) 419
cancer therapies (416) 416
melanoma - immunology (415) 415
immune checkpoint (413) 413
advanced melanoma (403) 403
skin neoplasms - pathology (398) 398
lymphocytes (392) 392
medicine, research & experimental (385) 385
t cells (385) 385
animals (384) 384
adverse events (378) 378
programmed cell death 1 receptor - antagonists & inhibitors (373) 373
complications and side effects (365) 365
prognosis (359) 359
antineoplastic agents - adverse effects (358) 358
aged, 80 and over (353) 353
dermatology (353) 353
ctla-4 antigen - antagonists & inhibitors (351) 351
health aspects (350) 350
melanoma - therapy (347) 347
apoptosis (345) 345
metastases (332) 332
medicine, experimental (329) 329
antibodies, monoclonal - administration & dosage (328) 328
vemurafenib (326) 326
medicine & public health (325) 325
lung cancer (321) 321
monoclonal antibodies (307) 307
antibodies (305) 305
untreated melanoma (303) 303
t-cells (301) 301
antigens (297) 297
melanoma - secondary (295) 295
cell lung-cancer (294) 294
multicenter (293) 293
oncology, experimental (292) 292
neoplasms - immunology (287) 287
double-blind (282) 282
ctla-4 blockade (280) 280
mutation (279) 279
ctla-4 antigen - immunology (276) 276
reports (276) 276
expression (271) 271
antibody (270) 270
cytotoxicity (266) 266
neoplasms - drug therapy (266) 266
pharmacology & pharmacy (264) 264
neoplasm staging (262) 262
trial (260) 260
toxicity (259) 259
article (256) 256
usage (256) 256
biomarkers (255) 255
melanoma - mortality (251) 251
antineoplastic combined chemotherapy protocols - therapeutic use (249) 249
retrospective studies (248) 248
neoplasm metastasis (244) 244
radiotherapy (238) 238
development and progression (236) 236
lymphocytes t (235) 235
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5635) 5635
French (100) 100
German (100) 100
Japanese (19) 19
Spanish (19) 19
Czech (10) 10
Polish (6) 6
Russian (6) 6
Danish (5) 5
Chinese (3) 3
Korean (3) 3
Dutch (2) 2
Hungarian (2) 2
Swedish (2) 2
Hebrew (1) 1
Icelandic (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2019, Volume 37, Issue 15, pp. 1355 - 1355
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1668 - 1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited... 
CRITERIA | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
La Revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, p. A74
MONCIMMUN Materiels et methodes Sur la periode de l'etude, 14 787 694 evenements indesirables ont ete rapportes dans VigiBase.sup.[R], dont 54 426 ont ete... 
Lymphocytes | Ipilimumab
Journal Article
JOURNAL OF ONCOLOGY PRACTICE, ISSN 1554-7477, 03/2019, Volume 15, Issue 3, pp. 159 - 161
Journal Article
HAUTARZT, ISSN 0017-8470, 10/2018, Volume 69, Issue Suppl 1, pp. 25 - 27
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1824 - 1835
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 12, pp. 1031 - 1031
Journal Article
Oncology, ISSN 0890-9091, 10/2016, Volume 30, Issue 10, p. 891
Journal Article
JOURNAL OF HEPATOLOGY, ISSN 0168-8278, 12/2018, Volume 69, Issue 6, pp. 1397 - 1398
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2018, Volume 29, Issue 2, pp. 514 - 515
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2908 - 2918
Journal Article
Cancer Cell, ISSN 1535-6108, 05/2018, Volume 33, Issue 5, pp. 853 - 861.e4
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 383 - 390
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with... 
METASTATIC MELANOMA | PEMBROLIZUMAB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | COMBINATION | IPILIMUMAB
Journal Article
Acta Oncologica, ISSN 0284-186X, 07/2019, Volume 58, Issue 7, pp. 962 - 966
Introduction: Phase III studies of PD-1 inhibitors have demonstrated remarkable improvements in the survival of patients with metastatic melanoma (MM). If... 
BRAF | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
NATURE REVIEWS NEPHROLOGY, ISSN 1759-5061, 06/2019, Volume 15, Issue 6, pp. 324 - 325
New data from the JAVELIN Renal 101 and KEYNOTE-426 trials provide evidence that immune-based combination therapy has superior efficacy to sunitinib... 
UROLOGY & NEPHROLOGY | IPILIMUMAB
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 615 - 617
According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II,... 
ONCOLOGY | IPILIMUMAB | STAGE-III
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2018, Volume 379, Issue 8, pp. 722 - 730
Journal Article